1Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence in Beijing, Xi'an and Shanghai[J]. Lancet, 2005, 365 (9 459) : 595 - 597.
2Inzelberg R, Nisipeanu P, Schechtman E. Practice parameter: initiation of treatment for Parkinson' s disease: an evidencebased review[J]. Nenrology, 2002,59(8):1292.
3Hadj Tahar A, Gregoire L, Bangassoro E, et al. Sustained cabergoline treatment reverses levodopa- induced dyskinesias in parkinsonian monkeys[J]. Clin Neuropharmacol, 2000, 23(4): 195 - 202.
4Wermuth L. A double - blind, placebo - controlled, randomized, multi- center study of pramipexole in advanced Parkinon's disease[ J ]. Eur J Neurol, 1998, 5(3) : 235 - 242.
5Weiner WJ, Factor SA, Jankovic J, et al. The long - term safety and efficacy of pramipexole in advanced Parkinson' s disease[ J ]. Parkinsonism Relat Disord, 2001, 7(2) : 115 - 120.
6Biglan KM, HoUoway RG. A review of pramipexole and its clinical utility in Parkinson's disease[J ]. Expert Opin Pharmacother, 2002, 3(2) : 197 - 210.
7Mai A, Artico M, Esposito M, et al. Synthesis and biological evaluation of enantiomerically pure oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors [ J ]. Farmaco, 2003,58(3): 231-241.
8Ebadi M, Sharma S, Shavali S, et al. Neuroprotective actions of selegiline[J]. J Neurosci Res, 2002, 67(3) :285 - 289.
9Rabey JM, Sagi I, Huherman M, et al. Rasagiline mesylate, a new MAO- B inhibitor for the treatment of Parkinson's disease: a double- blind study as adjunctive therapy to levodopa[J ]. Clin Neuropharmacol, 2000, 23(6) : 324 - 330.
10Sairam K, Saravanan KS, Banerjee R, et al. Non- steroidal antiinflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1 - methyl - 4 - phenyl pyridinium induced dopaminergic neurotoxiciw in rats[J ]. Brain Res, 2003, 966(2): 245 - 252.
二级参考文献11
1Schaltenbrand G. Wahren W. Atlas for stereotaxy of the human brain. 2nd edition. Stuttgart: Thieme, 1977.
2Alvarez Gonzalez L, Macias R, Guridi J, et al. Lesion of the subthalamic nucleus in Parkinson's disease: long term follow-up.Ann Neurol, 1999, 46:492-493
3Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord, 2001, 16( 1 ) :72-78
4Lenz FA, Tasker RR, Kwan HC, et al. Single unit analysis of the human ventral thalamus nuclear group: correlation of thalamic "tremor cells" with the 3-6 Hz component of parkinsonian tremor. J Neurosci, 1988, 8: 754-764.
5PA Starr, JL Vitek, RA Bakay. Deep brain stimulation for movement disorders. Neurosurgery Clinics of North America, 1998, 9 (2):381-402.
6MS Okun, JL Vitek. Lesion therapy for Parkinsong disease and other movement disorders: update and controversies. Mov Disord, 2004,19(4) : 375-389.
7Oh MY,Hodaie M,Kim SH,et al.Deep brain stimulator electrodes used for lesioningproof of principle. Neurosurgery, 2001, 49 (2): 363-367.
8Favre J,Burchiel KJ,Taha JM,et al. Outcome of unilateral and bilateral pallidotomy for Parkinson's disease:patient assessment. Neurosurgery,2000, 46 (2): 344-353.
9Dowsey-Limousin P,Pollak P.Deep brain stimulation in the treatment of Parkinson's disease:a review and update. Clin Neurosci Res,2001, 521-526.
6Nakamum H. Thioredoxin and its related molecules: update 2005 [ J ] . Antioxid Redox S/gna/,2005, 7:823 -828.
7Lillig CH, Holmga'en A. Thioredoxin and related m0lecules--from biology to health and disease [J]. Antiozid Redox Signal,2007, 9:25-47.
8Ranjita B, Sherer- Todd B, Gillian MK, et al. Chronic systemic pesticide exposure reproduces features of Parkinsen' s disease [ J]. Nature neurosc/enes,2000,3 (12) :1301 - 1306.
9Powis G, Montfort WR. Properties and biological activities of thi- oredoxins [ J ]. Annu Rev Pharmacol Tox/co/,2001, 41 : 261 - 295.
10Saitoh M, Nishitoh H, Fujii M,et a/. Mammalian thioredoxin is a direct inhibitor of apoptosis signal regulating kinase (ASK) 1 [J].EMBO J, 1998, 17:2596 -2606.
